Research programme: immunotherapeutics - Formula PharmaceuticalsAlternative Names: C.I.K.-CAR.CD19; C.I.K.-CAR.CD23; C.I.K.-CAR.CD33
Latest Information Update: 11 Aug 2015
At a glance
- Originator University of Milan Bicocca
- Developer Formula Pharmaceutical
- Mechanism of Action Cytokine-induced killer cell replacements; IgE receptor modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Acute lymphoblastic leukaemia; Acute myeloid leukaemia; Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma; Solid tumours
Most Recent Events
- 03 Aug 2015 Formula Pharmaceuticals and the Max Delbrück Center for Molecular Medicine enters into an exclusive licensing agreement and strategic collaboration to develop cytokine induced killer cell based CAR immunotherapies
- 11 May 2015 Formula Pharmaceuticals in-licenses allogeneic, non-viral chimeric antigen receptor (CAR) technology platform from University of Milano-Bicocca